Zevra Therapeutics, Inc. Common Stock
ZVRA Real Time Price USDRecent trades of ZVRA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by ZVRA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: D-amphetamine compounds, compositions, and processes for making and using the same Sep. 17, 2024
-
Patent Title: Dextrorphan prodrugs and processes for making and using them Jun. 18, 2024
-
Patent Title: Ketamine compounds and processes for making and using them Sep. 12, 2023
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of ZVRA in WallStreetBets Daily Discussion
Recent insights relating to ZVRA
Recent picks made for ZVRA stock on CNBC
ETFs with the largest estimated holdings in ZVRA
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ZVRA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.